These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 3461178

  • 1. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
    Kawano F, Tejima Y, Tajima H, Lee SY, Shiozaki A, Nakai R, Chyosa M, Sawada T, Maeda Y, Mizokuni T.
    Rinsho Ketsueki; 1986 Mar; 27(3):315-20. PubMed ID: 3461178
    [No Abstract] [Full Text] [Related]

  • 2. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
    Takahashi I, Yorimitsu S, Inagaki T, Sekito N, Hayashi N, Nishimura M, Aoyama S, Nakada H, Ohmoto E, Uchida K.
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576
    [Abstract] [Full Text] [Related]

  • 3. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M, Owada N, Sasaki R, Sakamoto S, Miura Y.
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [A case of refractory acute lymphocytic leukemia responded to an intermediate-dose of cytosine arabinoside (ID Ara-C) therapy].
    Hirota Y, Shibuya T, Ohhara N, Okamura S, Iwagiri R, Tada Y, Otsuka T, Nagano M, Tsuda Y, Niho Y.
    Rinsho Ketsueki; 1986 Jun; 27(6):941-6. PubMed ID: 3463812
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of a case of childhood acute non-lymphocytic leukemia (ANLL) using high-dose cytosine arabinoside for intensification of early therapy].
    Imashuku S, Nakajima T, Morimoto S, Hibi S, Todo S, Morioka Y, Sugimoto T.
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):527-30. PubMed ID: 3813580
    [Abstract] [Full Text] [Related]

  • 8. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M, Tokyo Children's Cancer Study Group.
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN, Fernández-Jurado A, Martino ML, Diéguez JC, Moreno MV, Quesada JA, Polo B, Cañavate M, Amian A, Prados D.
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
    Ohshima A, Yoshida K, Sato T, Miyazaki S, Yanagisawa M, Nakayama Y, Takahashi T, Mamiya S, Fukusima Y, Miura AB.
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405
    [Abstract] [Full Text] [Related]

  • 15. Phase II-study for treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
    Jehn U, Heinemann V.
    Anticancer Res; 1993 Jan; 13(2):379-81. PubMed ID: 8517650
    [Abstract] [Full Text] [Related]

  • 16. ["A-triple-V" in refractory or relapsed acute myelocytic leukemia].
    Miyawaki S, Nemoto K, Wakamatsu R, Baba N, Yashiro K, Uchida S, Nakura M, Karasawa M, Takada M, Tanaka H.
    Rinsho Ketsueki; 1987 Jan; 28(1):34-9. PubMed ID: 3471982
    [No Abstract] [Full Text] [Related]

  • 17. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 18. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of childhood acute non-lymphocytic leukemia with the AVC regimen (adriamycin, vincristine and cytosine arabinoside)].
    Tonouchi T, Toyoda Y, Mimaya J.
    Rinsho Ketsueki; 1987 Sep; 28(9):1528-32. PubMed ID: 3437513
    [No Abstract] [Full Text] [Related]

  • 20. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Polish Adult Leukemia Group.
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.